skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Journal Article · · European Journal of Cancer (1990)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Sponsoring Organization:
USDOE Office of Science (SC), Nuclear Physics (NP)
OSTI ID:
1778496
Journal Information:
European Journal of Cancer (1990), Journal Name: European Journal of Cancer (1990) Vol. 126 Journal Issue: C; ISSN 0959-8049
Publisher:
ElsevierCopyright Statement
Country of Publication:
United Kingdom
Language:
English

References (21)

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial journal May 2012
Trends in survival for patients with metastatic soft-tissue sarcoma journal October 2010
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial journal January 2018
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) journal August 2015
Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers: Outcome of 29 Sarcoma Subtypes journal December 2017
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study journal January 2019
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma journal August 2018
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial journal December 2016
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study journal June 2011
Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group journal January 2001
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial journal April 2016
Soft-Tissue Sarcomas in Adults journal August 2005
Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing journal August 2011
Olaratumab failure in sarcomas: what are the lessons learned? journal August 2019
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity journal July 2007
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials journal December 2017
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up journal October 2018
Regorafenib for Gastrointestinal Malignancies: From Preclinical Data to Clinical Results of a Novel Multi-Target Inhibitor journal February 2013
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules journal September 2009
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for res: HRQoL of Pazopanib in Pretreated STS journal May 2015
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial journal July 2016

Similar Records

A Phase III, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial of d-Threo-Methylphenidate HCl in Brain Tumor Patients Receiving Radiation Therapy
Journal Article · Sat Dec 01 00:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1778496
+9 more
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: A randomized, double-blind, placebo controlled trial in prostate cancer patients
Journal Article · Thu Dec 01 00:00:00 EST 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1778496
+1 more
Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy
Journal Article · Mon Apr 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1778496
+6 more

Related Subjects